Curated News
By: NewsRamp Editorial Staff
May 15, 2024
Orthocell Achieves 98.6% Success Rate in Striate Dental Membrane Study
TLDR
- Orthocell's Striate+™ dental membrane achieves 98.6% success rate in clinical study, positioning the company as a leader in guided bone regeneration for dental implants.
- The resorbable collagen membrane, Striate+™, enables high-quality bone and tissue repair, validated through a post-market clinical study with 99 patients.
- The success of Striate+™ will enhance visibility among dental professionals, leading to better outcomes for patients in need of bone and tissue regeneration procedures.
- Orthocell's Striate+™ dental membrane has been validated as a leading solution in bone and tissue regeneration, contributing to the betterment of medical procedures and patient outcomes.
Impact - Why it Matters
The success of Orthocell's Striate+™ membrane in the clinical study is significant for patients, dental professionals, and the company. It signifies a breakthrough in bone and tissue regeneration, offering potential for improved outcomes in dental implant procedures and reinforcing Orthocell's position in the market. The findings also contribute to the re-certification of EU market approval, ensuring the product's continued availability for patients in need of dental implant solutions.
Summary
Orthocell Ltd CEO Paul Anderson discusses the 98.6% success rate in a clinical study for its Striate+™ dental membrane. The study validates the membrane's effectiveness in bone and tissue regeneration, positioning it as a leading solution for dental implants. The results will be presented at the EAO annual meeting and contribute to the re-certification of EU market approval.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Orthocell Achieves 98.6% Success Rate in Striate Dental Membrane Study
